MedTrace Logo

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

NCT07541833 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (HOCM) receiving cibenzoline in Japan

Conditions

Interventions

DRUG

Mavacamten

According to the product label

Sponsors & Collaborators

Principal Investigators

  • Bristo Myers Squibb · Bristo Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-05
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07541833 on ClinicalTrials.gov